Academic Journal
Q1Osteoporosis International
About Osteoporosis International
Osteoporosis International is a scholarly journal published by Springer Science and Business Media Deutschland GmbH. SCImago 2025 lists it in Q1, with an SJR of 1.736 and H-index of 208.
Coverage: 1990-2026. Research categories: Endocrinology, Diabetes and Metabolism (Q1); Medicine (miscellaneous) (Q1).
Source-backed journal facts
Topics in published research
Bone health and osteoporosis research; Hip and Femur Fractures; Bone health and treatments; Bone Metabolism and Diseases; Vitamin D Research Studies; Parathyroid Disorders and Treatments.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
5,090.00 USD; 3,990.00 EUR; 3,190.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Letter to the Editor regarding “AI-derived bone mineral density from standard radiographs compared with DXA for fracture prediction in a 10-year real-world cohort study”
Kun Zhang
2026-10-05 · DOI: 10.1007/s00198-026-08232-xThe phenotype of pelvic and acetabular fractures in adults aged 50 and older: a national database analysis in the Netherlands
M. I. Lommerse, S. J. B. van der Jagt, H. J. Schuijt, J. P. van den Bergh et al.
2026-10-05 · DOI: 10.1007/s00198-026-08221-0Interaction between vitamin D and the growth hormone/insulin-like growth factor 1 axis in children: a systematic review and meta-analysis
Qiutong Song, Hanqi Lv, Yuheng Li, Yueyang Zhao et al.
2026-10-03 · DOI: 10.1007/s00198-026-08225-wOsteoCHAT: real-world patient evaluation and benchmarking of a guideline-grounded osteoporosis chatbot
Nils Schulz, Martin Gehlen, Karin Mahn, Björn Bühring et al.
2026-10-03 · DOI: 10.1007/s00198-026-08247-4Prevalence, risk factors and adverse health outcomes of osteosarcopenia in middle-aged and older adults with type 2 diabetes mellitus—a scoping review
Alvin Wai Kit Tan, Chia Siong Wong, Helen Elizabeth Smith, Yasmin Lynda Munro et al.
2026-10-03 · DOI: 10.1007/s00198-026-08228-7Denosumab—efficacy, safety, persistence and sequential strategies—a systematic review
Natasha Amran Laursen, Anne Sophie Sølling, Torben Harsløf, Bente L. Langdahl et al.
2026-10-02 · DOI: 10.1007/s00198-026-08237-6Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity
Mehmet Serkan Kılıçoğlu
2026-10-02 · DOI: 10.1007/s00198-026-08246-5Author Response to “Interpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance”
Hirotaka Koyanagi, Shohei Tsujino, Chigusa Sawamura, Katsunori Tozuka et al.
2026-10-02 · DOI: 10.1007/s00198-026-08233-wFrom prescription claims to treatment gaps after hip fracture: methodological considerations
Mehmet Serkan Kılıçoğlu
2026-10-02 · DOI: 10.1007/s00198-026-08254-5Differential efficacy of initial versus sequential combination of denosumab and teriparatide in osteoporosis at high fracture risk
Xin-ping Li, Rong Chen, Cheng Cheng, Jingyi Wang et al.
2026-10-02 · DOI: 10.1007/s00198-026-07979-7Modern pharmacological management of Osteoporosis: from monotherapy to sequential and combination approaches in postmenopausal women
Valeria Rella, Cinzia Rotondo, Raffaele Barile, Antonello Trotta et al.
2026-10-01 · DOI: 10.1007/s00198-026-08236-7Efficacy of sequential romosozumab–denosumab therapy in patients on hemodialysis: association with bone mineral density improvement and TRACP-5b rebound
Rie Kiyosumi, Kana Koinuma, Yuka Nodaira, Naofumi Ikeda et al.
2026-10-01 · DOI: 10.1007/s00198-026-08240-xDecreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis
Tarek Haj Shehadeh, Mustapha El Zeini, Tarek Elzomor, Yusuf Rashid et al.
2026-09-29 · DOI: 10.1007/s00198-026-08229-6Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure
Tomonori Kobayakawa, Hiroto Takenaka, Takaomi Kobayashi, Yukio Nakamura et al.
2026-09-28 · DOI: 10.1007/s00198-026-08241-wImpact of orthogeriatric care: prescription patterns in hospitalized older adults
Sofia Mendes-Piteira, Filipa Fialho Reis, Hugo Alexandre Ferreira, Catarina Oliveira et al.
2026-09-28 · DOI: 10.1007/s00198-026-08244-7A territorially coordinated, eHealth-supported fracture liaison service following femur fragility fracture: a pilot randomised controlled trial
Jordi Martín Marcuello, Alessio Rodolico, María Laura Britez Carli, Mireia Puig Campmany et al.
2026-09-28 · DOI: 10.1007/s00198-026-08219-8Demographic and clinical differences between individuals with and without DXA scans in Denmark
Sally Søgaard Andersen, Annika Vestergaard Kvist, Mia Daugaard Madsen, Peter Vestergaard et al.
2026-09-26 · DOI: 10.1007/s00198-026-08222-zLetter of response to “Postpartum timing of teriparatide initiation and BMD response in pregnancy‑ and lactation‑associated osteoporosis: an observational study”
Christopher S. Kovacs
2026-09-25 · DOI: 10.1007/s00198-026-08250-9Chronic hyponatremia and skeletal vulnerability: bone loss, fragility fracture risk, and therapeutic uncertainties
Lucas Maciel de Almeida Corrêa, Luiggi Kevin Virgino Brandão, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa et al.
2026-09-24 · DOI: 10.1007/s00198-026-08209-wInterpreting romosozumab for cancer treatment-induced bone loss: measurement, missing data, and surveillance
Mehmet Serkan Kılıçoğlu
2026-09-24 · DOI: 10.1007/s00198-026-08234-9Reviews
Community Reviews
Version History
October 4, 2026 at 8:49 pm
September 25, 2026